AMBU LAUNCHES HD CYSTOSCOPY SOLUTION IN THE U.S.
Following the FDA clearance for the Ambu® aScope™ 5 Cysto HD solution, Ambu introduces its HD cystoscope to urologists in the USA, expanding the urology offering and meeting advanced needs for cystoscopy procedures requiring superior image quality.
Today, Ambu announces FDA clearance of its newest cystoscopy solution, the Ambu® aScope™ 5 Cysto HD, in combination with the company’s two full-HD endoscopy systems, Ambu® aView™ 2 Advance and Ambu® aBox™ 2.
The clearance grants U.S. healthcare professionals access to Ambu’s expanded urology portfolio, which now features three single-use endoscopes – Ambu® aScope™ 4 Cysto, Ambu® aScope™ 5 Uretero and Ambu® aScope™ 5 Cysto HD – fully integrated with Ambu’s portfolio of endoscopy systems.
The Ambu® aScope™ 5 Cysto HD solution is specifically designed to support urologists during procedures requiring superior imaging, such as select bladder cancer screenings and bladder tumour removals. This is supported by the solution’s high-resolution camera chip and advanced image enhancement technology.
Ambu obtained European regulatory clearance (CE mark) of the solution in October 2023. Following the recent FDA clearance, Ambu plans to engage directly in a commercial launch in the USA, the company’s biggest market. The launch includes both the HD cystoscope and Ambu’s ureteroscope, which is designed to function as an all-purpose endoscope for urologists performing both diagnostic and therapeutic ureteroscopy procedures.
The combination of Ambu® aScope™ 4 Cysto, the Ambu® aScope™ 5 Cysto HD and Ambu® aScope™ 5 Uretero now provides urologists and their staff an extensive portfolio of advanced solutions that address a wide range of patient needs in urology. From development and manufacturing to distribution and sale, Ambu owns the entire product lifecycle for its full endoscopy portfolio.
The Ambu® aScope™ 4 Cysto will continue to serve a wide range of standard cystoscopy procedures across outpatient clinics and hospitals, while the Ambu® aScope™ 5 Cysto HD will target specific procedures requiring superior image quality. It will be priced at a premium, compared to the Ambu® aScope™ 4 Cysto.
Ambu CEO, Britt Meelby Jensen, is excited about the upcoming U.S. launch of Ambu’s expanded urology offering:
"Our expanded urology portfolio underscores our commitment to meeting the evolving needs of urologists and nurses, ensuring they have the best solutions at their disposal for unlocking workflow efficiency and enhancing patient outcomes. Our expanded urology portfolio targets a wide range of needs, and I am excited about the potential it holds for transforming patient care in the field."
BRITT MEELBY JENSEN
Chief Executive Officer, Ambu
Keywords
Contacts
Anders HjortHead of Investor Relations
Tel:+45 2892 8881anhj@ambu.comTine Bjørn SchmidtHead of Corporate Communications
Tel:+45 2264 0697tisc@ambu.comDocuments
About Ambu
Since 1937, Ambu has been rethinking solutions together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 4,900 people in Europe, North America, Latin America and Asia Pacific. For more information, please visit Ambu.com.
Subscribe to releases from Ambu A/S
Subscribe to all the latest releases from Ambu A/S by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Ambu A/S
FRIENDLY REMINDER: AMBU CAPITAL MARKETS DAY 202510.9.2025 12:48:28 CEST | Press release
This is a friendly reminder to secure your seat for in-person attendance at Ambu’s Capital Markets Day, taking place on 1 October 2025 from 10:00 to 16:30 CEST at our headquarters in Denmark, Baltorpbakken 13, 2750 Ballerup. We look forward to welcoming institutional investors, analysts, and financial media for a day of insights on strategy and market opportunities. Furthermore, it is an opportunity to meet with the broader Executive Leadership Team, as well as key external speakers. Finally, there will be a product demonstration at the end of the event, offering participants the opportunity to experience Ambu’s solutions firsthand. All presentations and Q&As are held from 10:00-15:00 CEST. The presentations will be held in English, and they will be recorded. After the event, the recorded presentations and the presentation materials will be published on Ambu’s website. The product demonstration will run from 15:00-16:30 CEST and will be for in-person attendees only. SIGN UP FOR IN-PERS
AMBU APPOINTS NEW PRESIDENT OF NORTH AMERICA REGION22.8.2025 07:10:00 CEST | Press release
Steven Block steps down; Scott Heinzelman appointed as new President to drive Ambu’s strong growth trajectory in North America.
AMBU CAPITAL MARKETS DAY 20257.8.2025 15:25:11 CEST | Press release
Ambu invites institutional investors, analysts, and financial media to the company’s Capital Markets Day on Wednesday 1 October 2025.
AMBU OBTAINS FDA CLEARANCE FOR FIRST-EVER SINGLE-USE FLEXIBLE CYSTO-NEPHROSCOPY SOLUTION19.6.2025 16:43:47 CEST | Press release
The FDA clearance for the Ambu® aScope™ 5 Cysto HD marks a historic milestone as the first ever single-use cysto-nephroscope to receive such clearance in the US. It follows the CE mark in Europe earlier this year, representing an important step forward in endoscopic technology and reinforcing Ambu’s commitment to innovation and advancement in urology care.
AMBU LAUNCHES FIRST-OF-ITS-KIND ENDOSCOPE RECYCLING PROGRAM TO ENHANCE WASTE REDUCTION IN HOSPITALS2.6.2025 10:27:09 CEST | Press release
Today, Ambu announces the launch of its new Ambu® Recircle program, teaming up with hospitals in both the US and the UK as the first key participants.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom